Helperby Therapeutics

Executive Summary

Helperby Therapeutics is a London-based, clinical-stage biopharmaceutical company addressing the urgent global threat of antimicrobial resistance (AMR). The company's innovative approach combines already approved antibiotics in synergistic formulations to combat WHO Critical and High Priority pathogens. This strategy aims to rejuvenate existing drugs, enhance their efficacy, reduce side effects, and delay the emergence of resistance. Founded in 2014, Helperby has progressed to Phase 1 clinical development, leveraging a risk-mitigated pathway by repurposing approved agents. With no disclosed funding or valuation, the company operates in a high-demand therapeutic area, potentially benefiting from regulatory incentives and public-private partnerships targeting AMR. Its focused pipeline and experienced management position it as a notable player in the AMR space, though early-stage risks remain.

Upcoming Catalysts (preview)

• Q3 2026Phase 1 top-line data readout for lead combination therapy60% success
• Q2 2026Grant or partnership announcement for AMR pipeline expansion50% success
• Q4 2026Regulatory designation (e.g., QIDP or fast track) from FDA or EMA70% success